Triesence FDA Approval History
FDA Approved: Yes (First approved November 29, 2007)
Brand name: Triesence
Generic name: triamcinolone acetonide
Dosage form: Injectable Suspension
Company: Alcon, Inc.
Treatment for: Temporal Arteritis, Uveitis
Triesence (triamcinolone acetonide) is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Development Timeline for Triesence
|Dec 3, 2007||Alcon Receives FDA Approval of Triesence Injectable Triamcinolone Suspension for Use in Eye Surgery|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.